Atsena Therapeutics Announces Late-Breaker Presentation at the AAO Annual Meeting

Atsena Therapeutics announced that data from the phase 1/2 clinical trial of ATSN-101 will be presented in a late breaking developments session during the Retina Subspecialty Day at the American Academy of Ophthalmology Annual Meeting (AAO 2022), which is being held September 30 - October 3, 2022 in Chicago.

ATSN-101, Atsena’s lead investigational gene therapy product formerly known as SAR439483, is being evaluated in patients with Leber congenital amaurosis caused by biallelic mutations in GUCY2D (LCA1). LCA1 is a monogenic eye disease that disrupts the function of the retina and results in early and severe vision impairment or blindness.

Details of the presentation are as follows:

Title: Safety and Efficacy of SAR439483 in Patients with Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D (LCA1)
Abstract Number: 30071742
Section: Section X: Late Breaking Developments, Part II
Date / Time: Saturday, October 1, 9:15 a.m. CST
Location: McCormick Place – Arie Crown
Presenter: Christine Nichols Kay, MD, Atsena Therapeutics